Acolbifene
Acolbifene (INN) (developmental code names EM-652, SCH-57068) is a nonsteroidal selective estrogen receptor modulator (SERM) which, as of 2015, is in phase III clinical trials for the treatment of breast cancer.[1][2]
Clinical data | |
---|---|
Other names | EM-652; SCH-57068 |
Drug class | Selective estrogen receptor modulator |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
ChEMBL | |
Chemical and physical data | |
Formula | C29H31NO4 |
Molar mass | 457.570 g·mol−1 |
3D model (JSmol) | |
| |
|
References
- Gauthier S, Cloutier J, Dory YL, Favre A, Mailhot J, Ouellet C, et al. (April 2005). "Synthesis and structure-activity relationships of analogs of EM-652 (acolbifene), a pure selective estrogen receptor modulator. Study of nitrogen substitution". Journal of Enzyme Inhibition and Medicinal Chemistry. 20 (2): 165–77. doi:10.1080/14756360500043448. PMID 15968821.
- "Acolbifene - Endoceutics". Adis Insight. Springer Nature Switzerland AG.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.